Alexandria Real Estate Equities, Inc. Enables the Discovery, Development and Delivery of New Innovative Medicines That Are Key to Addressing Significant Unmet Medical Need
Alexandria Real Estate Equities (NYSE: ARE), a leading owner and developer of life science campuses, continues to support the development of new therapies in the $5 trillion life science industry. The company's tenants are responsible for five out of six innovative medicines approved by the FDA in 2024, and over 80% of FDA approvals for innovative medicines this year. Since 2013, Alexandria tenants have developed half of all FDA-approved novel therapies.
The company highlights the significant growth in innovative medicine approvals, with a 286% increase between 2017-2020 and 2021-YTD 2024 periods. The immunology market is expected to grow from $103 billion in 2024 to $257 billion by 2032, becoming the second-largest biopharmaceutical spending area by 2028.
Alexandria Real Estate Equities (NYSE: ARE), un importante proprietario e sviluppatore di campus scientifici, continua a sostenere lo sviluppo di nuove terapie nell'industria delle scienze della vita da 5 trilioni di dollari. I locatari dell'azienda sono responsabili di cinque dei sei medicinali innovativi approvati dalla FDA nel 2024, e oltre l'80% delle approvazioni della FDA per medicinali innovativi di quest'anno. Dal 2013, i locatari di Alexandria hanno sviluppato la metà di tutte le nuove terapie approvate dalla FDA.
L'azienda evidenzia la significativa crescita nelle approvazioni di medicine innovative, con un aumento del 286% tra il 2017 e il 2020 e nei periodi dal 2021 a oggi del 2024. Si prevede che il mercato dell'immunologia cresca da 103 miliardi di dollari nel 2024 a 257 miliardi di dollari entro il 2032, diventando il secondo settore in termini di spesa biopharmaceutica entro il 2028.
Alexandria Real Estate Equities (NYSE: ARE), un importante propietario y desarrollador de campus de ciencias de la vida, continúa apoyando el desarrollo de nuevas terapias en la industria de las ciencias de la vida de 5 billones de dólares. Los inquilinos de la empresa son responsables de cinco de los seis medicamentos innovadores aprobados por la FDA en 2024 y más del 80% de las aprobaciones de la FDA para medicamentos innovadores este año. Desde 2013, los inquilinos de Alexandria han desarrollado la mitad de todas las nuevas terapias aprobadas por la FDA.
La empresa destaca el significativo crecimiento en las aprobaciones de medicamentos innovadores, con un aumento del 286% entre los períodos 2017-2020 y 2021-hasta la fecha de 2024. Se espera que el mercado de inmunología crezca de 103 mil millones de dólares en 2024 a 257 mil millones de dólares para 2032, convirtiéndose en la segunda área de gasto biofarmacéutico más grande para 2028.
알렉산드리아 리얼 에스테이트 이퀴티스 (NYSE: ARE), 생명 과학 캠퍼스의 주요 소유자이자 개발자로서, 5조 달러 규모의 생명 과학 산업에서 새로운 치료법 개발을 지원하고 있습니다. 이 회사의 세입자는 2024년 FDA에서 승인된 혁신적인 의약품 6개 중 5개를 담당하며, 올해 혁신적인 의약품에 대한 FDA 승인 중 80% 이상을 차지하고 있습니다. 2013년 이후 알렉산드리아의 세입자는 FDA에 의해 승인된 모든 새로운 치료법의 절반을 개발했습니다.
회사는 혁신적인 의약품 승인에서 2017-2020년과 2021년부터 현재까지의 286% 증가라는 중대한 성장을 강조합니다. 면역학 시장은 2024년 1030억 달러에서 2032년 2570억 달러로 성장할 것으로 예상되며, 2028년까지 생물 제약 지출 분야의 두 번째로 큰 영역이 될 것입니다.
Alexandria Real Estate Equities (NYSE: ARE), un propriétaire et développeur de campus en sciences de la vie de premier plan, continue de soutenir le développement de nouvelles thérapies dans l'industrie des sciences de la vie de 5 billions de dollars. Les locataires de l'entreprise sont responsables de cinq des six médicaments innovants approuvés par la FDA en 2024, et plus de 80 % des approbations de la FDA pour des médicaments innovants cette année. Depuis 2013, les locataires d'Alexandria ont développé la moitié de toutes les thérapies novatrices approuvées par la FDA.
L'entreprise souligne la croissance significative des approbations de médicaments innovants, avec une augmentation de 286 % entre les périodes 2017-2020 et 2021-à ce jour 2024. Le marché de l'immunologie devrait passer de 103 milliards de dollars en 2024 à 257 milliards de dollars d'ici 2032, devenant ainsi le deuxième domaine de dépenses biopharmaceutiques d'ici 2028.
Alexandria Real Estate Equities (NYSE: ARE), ein führender Eigentümer und Entwickler von Lebenswissenschafts-Campus, unterstützt weiterhin die Entwicklung neuer Therapien in der 5-Billionen-Dollar-Lebenswissenschaftsbranche. Die Mieter des Unternehmens sind verantwortlich für fünf von sechs innovativen Arzneimitteln, die 2024 von der FDA genehmigt wurden, und über 80% der FDA-Zulassungen für innovative Arzneimittel in diesem Jahr. Seit 2013 haben die Mieter von Alexandria die Hälfte aller von der FDA genehmigten neuartigen Therapien entwickelt.
Das Unternehmen hebt das signifikante Wachstum bei den Genehmigungen innovativer Medikamente hervor, mit einem Anstieg von 286% zwischen 2017-2020 und 2021-bis heute 2024. Der Immunologiemarkt wird voraussichtlich von 103 Milliarden Dollar im Jahr 2024 auf 257 Milliarden Dollar im Jahr 2032 wachsen und bis 2028 der zweitgrößte Bereich der biopharmazeutischen Ausgaben werden.
- Tenants responsible for 5 out of 6 FDA-approved innovative medicines in 2024
- Tenants account for over 80% of FDA approvals for innovative medicines in 2024
- Strong market position in growing $5 trillion life science industry
- 286% increase in FDA innovative medicine approvals between 2017-2020 and 2021-YTD 2024
- None.
Insights
This news is primarily about ARE's strategic positioning in the life sciences real estate sector and their tenant achievements. Key metrics show strong performance:
- ARE tenants developed
50% of FDA-approved therapies since 2013 - In 2024, tenants account for
80% of FDA approvals for innovative medicines - The immunology market is projected to grow from
$103 billion to$257 billion by 2032
The company's strategic focus on life science mega campuses in premium locations positions them well to capture growth in the
The broader healthcare context presents significant growth opportunities for ARE's business model. With only
"As innovative medicine approvals by the FDA have ramped up over the past several years, the promise of next-generation medicine is being realized in key areas of unmet need, including oncology, neurodegenerative and psychiatric disorders and diseases of the immune system, which means expanded treatment options and enhanced quality of life for patients," said Joel S. Marcus, executive chairman and founder of Alexandria Real Estate Equities, Inc. and Alexandria Venture Investments. "Innovation in medicine is the only effective path to solving the over
The field of immunology and inflammation has emerged as fundamental to how we approach a wide array of human diseases. Recent breakthroughs in our understanding of the immune system are leading to revolutionary therapies and opening new frontiers in medical science. Moreover, immunology is predicted to become the second-largest area of biopharmaceutical spend by 2028, behind oncology, and the global immunology market is expected to more than double from nearly
In light of the paramount importance of this burgeoning field,
About Alexandria Real Estate Equities, Inc.
Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500® company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. As the pioneer of the life science real estate niche with our founding in 1994,
Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, without limitation, statements regarding
CONTACT: Joel S. Marcus, Executive Chairman & Founder, (626) 578-9693, jmarcus@are.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/alexandria-real-estate-equities-inc-enables-the-discovery-development-and-delivery-of-new-innovative-medicines-that-are-key-to-addressing-significant-unmet-medical-need-302296686.html
SOURCE Alexandria Real Estate Equities, Inc.
FAQ
What percentage of FDA-approved innovative medicines in 2024 came from Alexandria Real Estate (ARE) tenants?
How much is the immunology market expected to grow according to Alexandria Real Estate (ARE)?